About ALS Biopharma

We are an emerging biotechnology company dedicated to the discovery of small-molecule therapeutics and diagnostics for the treatment of the debilitating neurological orphan indication of amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). We incorporate modern aspects of drug discovery including compound library synthesis and screening. In partnership with top academic and industrial laboratories, ALS Biopharma, LLC is researching both small molecule and biologic protein-based approaches to treat the disease.


ALS Biopharma
3805 Old Easton Road
Doylestown, PA 18902
(215) 589-6416

Location and Facilities

We are affiliated with the Pennsylvania Drug Discovery Institute (www.padrugdiscovery.org) at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA (www.pabiotechbc.org).

Our laboratories at the PBC include a complete array of chemistry and biochemistry tools and equipment such as a real time PCR, laminar flow hoods, table top centrifuges, Thermofinnagan LCQ and ABI Qtrap Mass Specs, Waters HPLC systems, a Biomek robot liquid handler, and other equipment that is routine for modern molecular biology, high throughput screening, and medicinal chemistry.

Recent Publications

Cassel, J. A.; Reitz, A. B. Ubiquilin-2 (UBQLN2) binds with high affinity to the C-terminal region of TDP-43 and modulates TDP-43 levels in H4 cells: Characterization of inhibition by nucleic acids and 4-aminoquinolines. Biochim. Biophys. Acta, 2013, 1834, 964-971.

Cassel, J. A.; Ilyin, S.; McDonnell, M. E.; Reitz, A. B. Novel Inhibitors of Heat Shock Protein Hsp70-Mediated Luciferase Refolding that Bind to DnaJ, Bioorg. Med. Chem. Lett. 2012, 20, 3609-3614.

Cassel, J. A.; McDonnell, M. E.; Velvadapu, V.; Andrianov, V.; Reitz, A. B. Characterization of a series of 4-aminoquinolines that stimulate caspase-7 mediated cleavage of TDP-43 and inhibit its function. Biochemie, 2012, 94, 1974-1981.

Cassel, J. A.; Ilyin, S.; McDonnell, M. E.; Reitz, A. B. Novel Inhibitors of Heat Shock Protein Hsp70-Mediated Luciferase Refolding that Bind to DnaJ., Bioorg. Med. Chem. Lett. 2012, 20, 3609-3614.

Pawlyk, A. C.; Cassel, J. A.; Reitz, A. B. Current Nervous System Related Drug Targets for the Treatment of Amyotrophic Lateral Sclerosis. Curr. Pharm. Des. 2010, 16, 2053.

Cassel, J. A.; Blass, B. E.; Reitz, A. B.; Pawlyk, A. C. Development of a Nonradiometric Assay for Nucleic Acid Binding to TDP-43 Suitable for High-Throughput Screening Using AlphaScreen® Technology. J. Biomolecular Screening, 2010, 15, 1099-1106.